Trials / Completed
CompletedNCT04637204
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
Treatment Patterns and Outcomes Among Advanced Renal Cell Carcinoma (aRCC) Patients Treated With Cabozantinib or Axitinib Therapy: Non Interventional, Retrospective Study Using Data From Public Health England's Cancer Analysis System
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,540 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib monotherapy in England using the existing data source, Cancer Analysis System (CAS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib | oral therapy |
| DRUG | Axitinib | oral therapy |
Timeline
- Start date
- 2020-11-24
- Primary completion
- 2020-12-11
- Completion
- 2020-12-11
- First posted
- 2020-11-19
- Last updated
- 2021-02-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04637204. Inclusion in this directory is not an endorsement.